Chengdu Jingze

Chengdu Jingze is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the development and commercialization of high-quality biosimilars and innovative biologics. The company's primary focus lies in ophthalmology, oncology, and metabolic diseases, with a robust pipeline targeting conditions such as age-related macular degeneration and various cancers. Its lead programs include biosimilars for blockbuster anti-VEGF therapies like ranibizumab and aflibercept, which are currently in advanced clinical stages. Chengdu Jingze leverages its proprietary mammalian cell expression platform to ensure efficient production and high similarity to reference products. The company aims to provide affordable, high-quality therapeutic options for patients in China and global markets.